PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
Clinical trial NCT06083857 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06083857
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-18
- Primary completion
- 2027-12-31
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.